drugset / Trial / NCT00208169
Abilify Therapy for Reducing Comorbid Substance Abuse
Non-randomizedSingle-groupOpen-labelTreatment
Summary
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: * Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) * Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale * Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 10 mg | — |
| Subject | Aripiprazole | Other / unclassified | 30 mg | — |